نتائج البحث - Paul DiSilvestro

تنقيح النتائج
  1. 1
    Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

    Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time? حسب Paul DiSilvestro, Angeles Alvarez Secord

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P

    Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P حسب Don S. Dizon, John A. Blessing, D. Scott McMeekin, Sudarshan Sharma, Paul DiSilvestro, Ronald D. Alvarez

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy

    Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Fa... حسب Peter G. Rose, James Java, Charles W. Whitney, Frederick B. Stehman, Rachelle Lanciano, Gillian Thomas, Paul DiSilvestro

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass

    Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass حسب Richard G. Moore, Michael Craig Miller, Paul DiSilvestro, Lisa M. Landrum, W Gajewski, John J. Ball, Steven J. Skates

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study

    A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynec... حسب Don S. Dizon, John A. Blessing, Richard T. Penson, Richard D. Drake, Joan L. Walker, Carolyn M. Johnston, Paul DiSilvestro, Amanda N. Fader

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

    A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass حسب Richard G. Moore, D. Scott McMeekin, Amy Brown, Paul DiSilvestro, Michael Craig Miller, W. Jeffrey Allard, W Gajewski, Robert J. Kurman, Robert C. Bast, Steven J. Skates

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

    Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study حسب Gini F. Fleming, Michael W. Sill, Kathleen M. Darcy, D. Scott McMeekin, J.T. Thigpen, Lisa Adler, Jonathan S. Berek, Julia Chapman, Paul DiSilvestro, Ira Horowitz, James V. Fiorica

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis: A Gynecologic Oncology Group Study

    Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited t... حسب Paul DiSilvestro, Shamshad Ali, Peter Craighead, Joseph A. Lucci, Yi-Chun Lee, David E. Cohn, Nicola M. Spirtos, Krishnasu S. Tewari, Carolyn Y. Muller, W Gajewski, Margaret M. Steinhoff, Bradley J. Monk

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial

    Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial حسب Mostafa Atri, Zheng Zhang, Farrokh Dehdashti, Susanna I. Lee, Shamshad Ali, Helga S. Marques, Wui-Jin Koh, Kathleen N. Moore, Lisa M. Landrum, Jae‐Weon Kim, Paul DiSilvestro, Eric Eisenhauer, Frederick M. Schnell, Michael A. Gold

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial

    Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial حسب Mostafa Atri, Zheng Zhang, Farrokh Dehdashti, Susanna I. Lee, Helga S. Marques, Shamshad Ali, Wui-Jin Koh, Robert S. Mannel, Paul DiSilvestro, Stephanie King, Michael L. Pearl, XunClare Zhou, Marie Plante, Katherine Moxley, Michael A. Gold

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis

    Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data... حسب Kathleen N. Moore, James Java, K.N. Slaughter, Peter G. Rose, Rachelle Lanciano, Paul DiSilvestro, J.T. Thigpen, Yi-Chun Lee, Krishnansu S. Tewari, Junzo Chino, Shelly Seward, David S. Miller, Ritu Salani, David H. Moore, Frederick B. Stehman

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

    FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study حسب Y. Jeske, Shamshad Ali, Sara A. Byron, Feng Gao, Robert S. Mannel, Rahel Ghebre, Paul DiSilvestro, Shashikant Lele, Michael L. Pearl, Amy P. Schmidt, Heather A. Lankes, Nilsa C. Ramirez, Golnar Rasty, Matthew A. Powell, Paul J. Goodfellow, Pamela M. Pollock

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

    Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer حسب John K. Chan, Mark F. Brady, Richard T. Penson, Helen Q. Huang, Michael J. Birrer, Joan L. Walker, Paul DiSilvestro, Stephen C. Rubin, Lainie P. Martin, Susan A. Davidson, Warner K. Huh, David M. O’Malley, Matthew Boente, Helen Michael, Bradley J. Monk

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

    Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial حسب Matthew A. Powell, Virginia L. Filiaci, Martee L. Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu S. Tewari, Larry J. Copeland, Angeles Alvarez Secord, David G. Mutch, Alessandro D. Santin, David Warshal, Nick M. Spirtos, Paul DiSilvestro, Olga B. Ioffe, David S. Miller

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

    811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 حسب Susana Banerjee, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, B-G. Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González‐Martín, Carol Aghajanian, William H. Bradley, Eileen Holmes, Elizabeth Lowe, Paul DiSilvestro

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-control... حسب Susana Banerjee, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González‐Martín, Carol Aghajanian, William H. Bradley, Eileen Holmes, Elizabeth Lowe, Paul DiSilvestro

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol

    Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol حسب William T. Creasman, Shamshad Ali, David G. Mutch, Richard J. Zaino, Matthew A. Powell, Robert S. Mannel, Floor Backes, Paul DiSilvestro, Peter A. Argenta, Michael L. Pearl, Shashikant Lele, Saketh R. Guntupalli, Steven Waggoner, Nick M. Spirtos, John F. Boggess, Robert P. Edwards, Virginia L. Filiaci, David S. Miller

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

    Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) حسب David S. Miller, Virginia L. Filiaci, Robert S. Mannel, David E. Cohn, Takashi Matsumoto, Krishnansu S. Tewari, Paul DiSilvestro, Michael L. Pearl, Peter A. Argenta, Matthew A. Powell, Susan Zweizig, David Warshal, Parviz Hanjani, Michael E. Carney, Helen Q. Huang, David Cella, Richard J. Zaino, Gini F. Fleming

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer حسب Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

    Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer حسب Daniela Matei, Virginia L. Filiaci, Marcus E. Randall, David G. Mutch, Margaret M. Steinhoff, Paul DiSilvestro, Katherine Moxley, Yong M. Kim, Matthew A. Powell, David M. O’Malley, Nick M. Spirtos, William Small, Krishnansu S. Tewari, William E. Richards, John Nakayama, Ursula A. Matulonis, Helen Q. Huang, David S. Miller

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: